Pipeline of Collaborative Proprietary Drug Discovery . . . - Schrödinger In December 2022, Schrödinger and Otsuka initiated a collaboration to discover novel medicines against undisclosed central nervous system (CNS) targets Schrödinger received an undisclosed upfront milestone payment and is eligible for additional milestones as the program progresses
About us - Schrödinger Founded in 1990 with continuous investment in R D, Schrödinger has pioneered a physics-based computational platform that enables the rapid and accurate discovery of high-quality, novel molecules for drug development and materials applications
Life science - Schrödinger Explore how Schrödinger solutions can solve research challenges across drug discovery application areas
Explore our latest software - Schrödinger What’s new in the Life Science Schrödinger Suite Release 2025-2 We release new platform usability and technological improvements quarterly New Crystal Structure Prediction interface to rank Z’=1 crystal polymorphs with high fidelity; New FEP+ Pose Builder workflow to automatically generate high-quality ligand alignments (Beta)